Superior therapeutic activity of TGF-β-induced extracellular vesicles against interstitial cystitis

J Control Release. 2022 Aug:348:924-937. doi: 10.1016/j.jconrel.2022.06.045. Epub 2022 Jun 29.

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic disease characterized by incapacitating pelvic pain. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are considered key mediators of the paracrine action of MSCs and show better biological activities than the parent MSCs, especially in the bladder tissue, which may be unfavorable for MSC survival. Here, we produced MSC-EVs using advanced three-dimensional (a3D) culture with exogenous transforming growth factor-β3 (TGF-β3) (T-a3D-EVs). Treatment with T-a3D-EVs led to significantly enhanced wound healing and anti-inflammatory capacities. Moreover, submucosal layer injection of T-a3D-EVs in chronic IC/BPS animal model resulted in restoration of bladder function, superior anti-inflammatory activity, and recovery of damaged urothelium compared to MSCs. Interestingly, we detected increased TGF-β1 level in T-a3D-EVs, which might be involved in the anti-inflammatory activity of these EVs. Taken together, we demonstrate the excellent immune-modulatory and regenerative abilities of T-a3D-EVs as observed by recovery from urothelial denudation and dysfunction, which could be a promising therapeutic strategy for IC/BPS.

Keywords: 3D; Anti-inflammatory; Awake cystometry; EVs; IC/BPS; MSCs; TGF-β1; TGF-β3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Cystitis, Interstitial* / therapy
  • Extracellular Vesicles*
  • Mesenchymal Stem Cells*
  • Transforming Growth Factor beta

Substances

  • Anti-Inflammatory Agents
  • Transforming Growth Factor beta